1. Home
  2. GYRE vs CTBI Comparison

GYRE vs CTBI Comparison

Compare GYRE & CTBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • CTBI
  • Stock Information
  • Founded
  • GYRE 2002
  • CTBI 1903
  • Country
  • GYRE United States
  • CTBI United States
  • Employees
  • GYRE N/A
  • CTBI N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • CTBI Major Banks
  • Sector
  • GYRE Health Care
  • CTBI Finance
  • Exchange
  • GYRE Nasdaq
  • CTBI Nasdaq
  • Market Cap
  • GYRE 997.3M
  • CTBI 922.9M
  • IPO Year
  • GYRE N/A
  • CTBI N/A
  • Fundamental
  • Price
  • GYRE $11.54
  • CTBI $53.88
  • Analyst Decision
  • GYRE
  • CTBI Strong Buy
  • Analyst Count
  • GYRE 0
  • CTBI 3
  • Target Price
  • GYRE N/A
  • CTBI $55.50
  • AVG Volume (30 Days)
  • GYRE 53.5K
  • CTBI 62.0K
  • Earning Date
  • GYRE 03-25-2025
  • CTBI 04-16-2025
  • Dividend Yield
  • GYRE N/A
  • CTBI 3.49%
  • EPS Growth
  • GYRE N/A
  • CTBI 5.73
  • EPS
  • GYRE N/A
  • CTBI 4.61
  • Revenue
  • GYRE $105,033,000.00
  • CTBI $237,609,000.00
  • Revenue This Year
  • GYRE $25.32
  • CTBI N/A
  • Revenue Next Year
  • GYRE $12.95
  • CTBI $6.00
  • P/E Ratio
  • GYRE N/A
  • CTBI $11.69
  • Revenue Growth
  • GYRE N/A
  • CTBI 7.36
  • 52 Week Low
  • GYRE $8.26
  • CTBI $38.53
  • 52 Week High
  • GYRE $26.37
  • CTBI $61.67
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 47.99
  • CTBI 45.03
  • Support Level
  • GYRE $12.09
  • CTBI $54.98
  • Resistance Level
  • GYRE $12.80
  • CTBI $56.96
  • Average True Range (ATR)
  • GYRE 0.56
  • CTBI 1.33
  • MACD
  • GYRE -0.00
  • CTBI -0.08
  • Stochastic Oscillator
  • GYRE 16.39
  • CTBI 40.77

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

About CTBI Community Trust Bancorp Inc.

Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and southcentral Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services.

Share on Social Networks: